CKD Bio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CKD Bio makes fermentation-derived ingredients and pharmaceutical raw materials used in medicines and health products.
Its customers include pharmaceutical manufacturers and related industries that incorporate these materials into finished products. The company is listed on KOSPI, South Korea's main stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
CKD Bio in five facts
What does CKD Bio do?
CKD Bio makes fermentation-derived ingredients and pharmaceutical raw materials used in medicines and health products.
Where is CKD Bio listed and in which sector?
CKD Bio (Korean name: 종근당바이오) trades under KRX code 063160 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is CKD Bio?
Its market capitalisation was US$54M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CKD Bio's latest annual revenue and operating profit?
For fiscal year 2025, CKD Bio reported revenue of US$120.8M, operating profit of US$2.7M and a net loss of US$2.2M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 6.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (preliminary) (fair disclosure)
CKD Bio filed provisional (unaudited) separate results for Q2 2026: revenue of US$28.9M (−0.3% year on year), an operating loss of US$3.52M (from a profit a year earlier) and a net loss of US$3.8M.
Earnings · Jul 31 - Operating results (preliminary) (fair disclosure)
CKD Bio filed provisional (unaudited) separate results for Q1 2026: revenue of US$27.5M (−4.3% year on year), an operating loss of US$1.15M (from a profit a year earlier) and a net loss of US$1.37M (from a profit a year earlier).
Earnings · Apr 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 30